Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Monoclonal Gammopathy of Undetermined Significance: early-phase trial registry
8 of 12 indexed Monoclonal Gammopathy of Undetermined Significance trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Monoclonal Gammopathy of Undetermined Significance: 12 US clinical trials tracked, 8 recruiting.
Monoclonal Gammopathy of Undetermined Significance is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition monoclonal-gammopathy-of-undetermined-significance
OPEN 8 | RECR 67% | LATE 0 | EARLY 3 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Monoclonal Gammopathy of Undetermined Significance lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Monoclonal Gammopathy of Undetermined Significance on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Monoclonal Gammopathy of Undetermined Significance is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Monoclonal Gammopathy of Undetermined Significance research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Monoclonal Gammopathy of Undetermined Significance enrolment sits around 200 participants.
Median target enrolment is 200 among the 12 trials that report a genuine target (sentinel values excluded). 4 of those (33.3%) plan for fewer than 100 participants.
-
Monoclonal Gammopathy of Undetermined Significance splits between interventional and observational designs.
7 interventional and 5 observational studies make up this index (58.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Ohio State University Comprehensive Cancer Center
NCT01408225
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
University of Miami
NCT05361694
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
NCT05136807
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
NCT06055894
Sleep Apnea in Patients With MGUS and MM
Michael Tomasson
NCT04114084
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
NCT02726750
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
NCT05640843
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
NCT04731844
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
NCT05831358
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
NCT04850846
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
NCT04920084
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
NCT04439006
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Monoclonal Gammopathy of Undetermined Significance records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Monoclonal Gammopathy of Undetermined Significance trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Monoclonal Gammopathy of Undetermined Significance page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Monoclonal Gammopathy of Undetermined Significance trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Monoclonal Gammopathy of Undetermined Significance trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Monoclonal Gammopathy of Undetermined Significance condition card totals 12 registered trials; most-linked intervention Multiple Myeloma Knowledge Questionnaires; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.